Radioactive Microspheres Emerge as a Curative Weapon Against Liver Cancer

For decades, yttrium-90 radioembolization has lived a double life in hepatology: celebrated as a gentle, minimally invasive palliative option for advanced liver cancer, yet quietly dismissed by many as a bridge or a comfort measure rather than a genuine shot at a cure. A new analysis of two large European prospective registries now suggests that this reputation is overdue for revision. In a pooled, retrospective, exploratory examination of 615 patients with hepatocellular carcinoma treated with transarterial radioembolization, or TARE, between 2015 and 2020, a small but striking group of patients ended up receiving treatment with genuinely curative intent, and a subset achieved durable complete responses with radiation alone.

The study, published in CVIR Oncology, draws on the CIRT registry spanning 27 sites across eight European countries and its French counterpart, CIRT-FR, which was conducted to help the French Health Authority evaluate reimbursement of yttrium-90 resin microspheres. Both registries were designed to capture real-world clinical practice rather than the tightly scripted conditions of a randomized trial, and that realism is precisely what makes the findings interesting. Physicians recorded their planned treatment intent at the start of therapy, but the researchers later reclassified each patient’s actual trajectory using predefined criteria covering transplantation, ablation, resection, or a sustained complete response lasting at least one year as measured by modified RECIST criteria.

The headline numbers tell a story about the gap between intention and outcome. Although 229 of the 615 patients, roughly 37 percent, were initially slated for curative-intent treatment pathways, only 40 patients, or 6.5 percent, ultimately met the retrospective curative-intent definition, while 93 percent were classified as palliative. Of those 40, half went on to liver transplantation after TARE, seven received ablation and two underwent resection. Most remarkably, 11 patients, 27.5 percent of the curative group, required no further treatment at all because TARE alone had produced a complete tumor response documented for at least a year.

That last figure carries particular weight given how the authors framed their expectations. Among 32 patients whose a priori plan was radiation segmentectomy, meaning planned curative yttrium-90 monotherapy, only one ultimately achieved a curative classification through subsequent transplantation. In other words, the patients who ended up cured by radiation alone were rarely the ones selected for that purpose in advance. Their complete responses were, in a sense, discovered rather than engineered, which the authors say underscores how little consensus currently exists on who will convert to a curative pathway after radioembolization and how urgently refined conversion criteria are needed.

The statistical analysis offers some clues. In multivariable logistic regression, three factors independently predicted placement in the curative-intent group: an ECOG performance status of zero, corresponding to fully active patients, carried an odds ratio of 0.44; having one to three tumors yielded an odds ratio of 0.39; and a total tumor volume below 150 cubic centimeters produced an odds ratio of 0.40. That 150 cubic centimeter threshold emerged from receiver operating characteristic analysis as one of two optimal cut points for separating curative from palliative patients, and it was selected for its higher specificity of 0.725. Notably, 72.5 percent of curatively treated patients fell below this volume, which is substantially larger than the roughly 65 cubic centimeter ceiling imposed by the classic Milan criteria for transplantation eligibility.

This discrepancy is central to the paper’s argument. The Milan criteria, which have governed transplant selection for hepatocellular carcinoma for nearly three decades, rest almost entirely on morphometric measurements, and the authors found no significant differences between their curative and palliative groups on Milan-based eligibility before treatment. Around 80 percent of the curatively managed patients were outside Milan criteria before TARE. The implication is that radioembolization can shrink tumors enough to pull patients back within transplant boundaries, and that tumor volume thresholds well beyond Milan’s limits, combined with biological markers such as alpha-fetoprotein and the ALBI grade of liver function, may better identify who stands to benefit. The authors point to emerging tools like the Metroticket 2.0 model as the kind of finer-grained metrics the field needs.

Dosimetry adds another technical layer to the story. Because absorbed radiation doses were not prospectively collected in the original registries, the team recalculated them retrospectively using the simplified Medical Internal Radiation Dose formula, dividing administered activity by tumor mass. Their surrogate analysis found that absorbed doses above 400 grays correlated with longer survival, a threshold repeatedly associated with complete response in prior literature. Crucially, 92.3 percent of patients who received doses above that level had tumors under 150 cubic centimeters, suggesting that the concentration of radiation achievable in smaller, more selectively targeted volumes is what drives these dramatic responses. Yet the data also showed that doses exceeding 400 grays remained effective in tumors up to about 150 cubic centimeters, roughly 6.6 centimeters in diameter, larger than many earlier studies had considered treatable at such intensities.

Survival outcomes reinforce the signal. Median overall survival was not reached in the complete response, resection, and ablation subgroups by the end of follow-up, and in the transplantation subgroup, 75 percent and 85 percent survival percentiles were reached at 37.1 and 11.4 months respectively, with only one death recorded in the resection and ablation group and none in the complete response group. By contrast, the palliative group’s median survival of 16.1 months compares favorably with the 8.0 and 8.8 months reported in the landmark SARAH and SIRveNIB randomized trials of radioembolization versus sorafenib in advanced disease, and aligns with more recent prospective figures of 13.9 months. The real-world palliative performance alone is notable, but the theoretical cure fractions achieved in a minority of patients are what will spark debate.

The authors are careful about the limits of their evidence. This was an exploratory, retrospective classification layered onto prospective observational data, with no harmonized definition of curative intent when the studies began. Baseline characteristics were collected only before TARE, alpha-fetoprotein levels were missing in more than a fifth of curative patients and more than 40 percent of palliative patients, and dosimetry relied on a surrogate calculation. The heterogeneity of post-TARE curative procedures across different national practices further complicates generalization. Still, the conclusion is clear and consequential: yttrium-90 radioembolization belongs not just in the palliative toolbox but across the full spectrum of curative-intent strategies for hepatocellular carcinoma, whether as a bridge to transplantation, a downstaging tool before resection or ablation, or, in carefully selected patients with small tumor burdens and good performance status, as a standalone therapy capable of eradicating the disease outright. The task now facing the field, the authors argue, is to marry morphometry, tumor biology, and personalized dosimetry into reliable criteria that can identify, before the first microsphere is injected, which patients will be among the lucky few whose cancer never returns.

Subject of Research: Curative-intent transarterial radioembolization with yttrium-90 in hepatocellular carcinoma

Article Title: Hepatocellular carcinoma patients treated with TARE monotherapy or combination therapy with curative intent: a retrospective, exploratory analysis of two European prospective studies

Article References: Helmberger, T., Arnold, D., Loffroy, R., Ronot, M., Sangro, B., Kolligs, F., Pellerin, O., Maleux, G., Peynircioglu, B., Schaefer, N., Bilbao, J. I., de Jong, N., Geyer, M., Zeka, B., Urdaniz, M., & Vilgrain, V. (2026). Hepatocellular carcinoma patients treated with TARE monotherapy or combination therapy with curative intent: a retrospective, exploratory analysis of two European prospective studies. CVIR Oncology, 2(1), Article 5. https://doi.org/10.1007/s44343-026-00035-5

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00035-5

Keywords: hepatocellular carcinoma, TARE, yttrium-90, radioembolization, liver transplantation, radiation segmentectomy, Milan criteria, dosimetry, tumor downstaging, locoregional therapy, complete response, CIRT registry